Global HIV-1 Screening Tests Market Size By Type (ELISA, Rapid Tests), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global HIV-1 Screening Tests Market was valued at USD 4.6 billion in 2023 and is projected to reach USD 7.8 billion by 2031, expanding at a CAGR of 6.7% during the forecast period from 2023 to 2031. The growing prevalence of HIV/AIDS worldwide, increased awareness and proactive screening initiatives, along with government and non-governmental health campaigns, are key factors fueling the market's expansion. HIV-1 screening tests are pivotal in early detection, enabling timely treatment, reducing transmission rates, and improving patient outcomes, thereby contributing to global health objectives.

Drivers:

1. Rising HIV Prevalence and Awareness Campaigns:

The increasing number of people living with HIV, especially in sub-Saharan Africa, Asia-Pacific, and parts of Latin America, has necessitated robust screening programs. Government initiatives and global collaborations like UNAIDS and WHO campaigns have significantly raised awareness, boosting the demand for screening tests.

2. Technological Advancements in Diagnostics:

Rapid developments in diagnostic technologies, such as fourth-generation ELISA, nucleic acid testing (NAT), and point-of-care rapid tests, have improved test accuracy, sensitivity, and accessibility, leading to increased adoption in both developed and developing regions.

3. Expansion of Public Health Infrastructure:

Efforts to enhance healthcare systems in emerging markets and increased funding for HIV/AIDS programs are expanding access to HIV screening services, especially in rural and underserved areas.

Restraints:

1. Social Stigma and Discrimination:

Despite awareness efforts, social stigma and fear of discrimination remain significant barriers to HIV-1 screening in many regions. These challenges often prevent individuals from getting tested and seeking care, limiting market penetration.

2. Limited Access in Low-Income Regions:

In some developing countries, inadequate healthcare infrastructure, supply chain disruptions, and limited availability of trained professionals hinder the effective deployment of HIV-1 screening programs.

Opportunity:

1. Integration of AI and Mobile Diagnostics:

The use of mobile health (mHealth) platforms and artificial intelligence for remote screening, diagnostics, and reporting is emerging as a transformative opportunity. These technologies improve test accessibility, reduce diagnostic errors, and enable mass population screening.

2. Expanding Screening in Non-Traditional Settings:

There is growing demand for HIV-1 testing in non-clinical environments such as home-testing kits, community centers, pharmacies, and mobile testing units, allowing greater privacy and convenience and encouraging more people to get tested.

Market by System Type Insights:

In 2023, the ELISA-based HIV-1 Screening Tests segment held the largest market share. These tests remain a gold standard for early-stage detection due to their high sensitivity and specificity. However, Rapid HIV-1 Screening Tests are projected to witness the highest growth during the forecast period, driven by increasing demand for decentralized testing and instant results in both clinical and home settings.

Market by End-Use Insights:

Hospitals and Diagnostic Laboratories accounted for the majority of the revenue share in 2023, due to their comprehensive testing capabilities and patient reach. The Home Care Settings segment, however, is expected to grow significantly, fueled by the rising preference for at-home testing options that offer confidentiality and convenience, particularly in urban regions.

Market by Regional Insights:

North America led the global HIV-1 screening tests market in 2023, supported by advanced healthcare infrastructure, favorable reimbursement policies, and proactive public health strategies. However, the Asia-Pacific region is expected to experience the highest growth during the forecast period, driven by rising disease burden, increasing healthcare investments, and expanding screening programs in countries like India, China, and Thailand.

Competitive Scenario:

Key players in the global HIV-1 screening tests market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., Siemens Healthineers, Ortho Clinical Diagnostics, Hologic Inc., Cepheid, bioMérieux SA, Thermo Fisher Scientific Inc., and Chembio Diagnostics, Inc. These companies are focused on expanding their test menus, developing point-of-care diagnostics, and pursuing partnerships to extend their global footprint.

Scope of Work – Global HIV-1 Screening Tests Market

Report Metric Details

Market Size (2023) USD 4.6 billion

Projected Market Size (2031) USD 7.8 billion

CAGR (2023–2031) 6.7%

Market Segments System Type (ELISA, Rapid, NAT), End-Use (Hospitals, Labs, Home Care)

Growth Drivers Rising HIV prevalence, tech advancements, global awareness initiatives

Opportunities Mobile diagnostics, at-home testing expansion

Key Market Developments:

2023: Abbott introduced a next-generation rapid HIV-1/2 test kit featuring enhanced sensitivity and reduced processing time for point-of-care settings.

2023: Roche Diagnostics launched a fully automated NAT-based HIV testing platform for high-volume labs, improving throughput and early-stage detection.

2024: Chembio Diagnostics received regulatory approval for its dual HIV-Syphilis rapid test in multiple African countries to support integrated disease screening programs.

FAQs:

1) What is the current market size of the Global HIV-1 Screening Tests Market?

The market was valued at USD 4.6 billion in 2023.

2) What is the major growth driver of the Global HIV-1 Screening Tests Market?

Key drivers include rising HIV prevalence and the adoption of advanced diagnostic technologies.

3) Which is the largest region during the forecast period in the Global HIV-1 Screening Tests Market?

North America dominated in 2023, while Asia-Pacific is expected to register the fastest growth.

4) Which segment accounted for the largest market share in the Global HIV-1 Screening Tests Market?

ELISA-based screening tests accounted for the largest share in 2023.

5) Who are the key market players in the Global HIV-1 Screening Tests Market?

Major players include Abbott, Roche, Siemens Healthineers, Bio-Rad, Thermo Fisher Scientific, and Chembio Diagnostics.

Let me know if you'd like a visual version (PDF/PowerPoint) or help with another report.